For the quarter ending 2025-09-30, HURA made $6,873,962 in revenue. -$7,104,544 in net income. Net profit margin of -103.35%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 4,968,596 | 4,926,936 | ||
| General and administrative expenses | 1,761,007 | 4,949,020 | ||
| Operating loss | 6,729,603 | 9,875,956 | ||
| Grant income | 138,299 | 322,655 | ||
| Interest expense | 16,532 | - | ||
| Interest income | 6,060 | 29,466 | ||
| Other expense | 185,019 | - | ||
| Change in fair value of kineta merger holdback shares | -315,660 | - | ||
| Total other (expense) income | -372,852 | 352,121 | ||
| Net loss | -7,102,455 | -9,523,835 | ||
| Series a preferred cash dividend | 2,089 | 2,089 | ||
| Net loss attributable to common stockholders | -7,104,544 | -9,525,924 | ||
| Earnings per share, basic | -0.14 | -0.21 | ||
| Earnings per share, diluted | -0.14 | -0.21 | ||
| Weighted average number of shares outstanding, basic | 50,666,430 | 44,555,095 | ||
| Weighted average number of shares outstanding, diluted | 50,666,430 | 44,555,095 | ||
TuHURA Biosciences, Inc. NV (HURA)
TuHURA Biosciences, Inc. NV (HURA)